Higher dose of ReNeuron's stem cells 'safe' in stroke
This article was originally published in Scrip
Executive Summary
In an update on its Phase I, dose-escalating trial of ReN001, a stem cell therapy for stroke, ReNeuron has said it has successfully treated the first patient in the next dose cohort.